SML1617
GSK2033
≥98% (HPLC), nuclear receptor liver-X-receptor (LXR) antagonist, powder
Synonym(s):
2,4,6-Trimethyl-N-[[3′-(methylsulfonyl)[1,1′-biphenyl]-4-yl]methyl]-N-[[5-(trifluoromethyl)-2-furanyl]methyl]benzenesulfonamide
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C29H28F3NO5S2
CAS Number:
Molecular Weight:
591.66
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Product Name
GSK2033, ≥98% (HPLC)
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 3 mg/mL, clear (warmed)
storage temp.
2-8°C
SMILES string
CS(C1=CC=CC(C2=CC=C(CN(S(C3=C(C)C=C(C)C=C3C)(=O)=O)CC4=CC=C(C(F)(F)F)O4)C=C2)=C1)(=O)=O
InChI
1S/C29H28F3NO5S2/c1-19-14-20(2)28(21(3)15-19)40(36,37)33(18-25-12-13-27(38-25)29(30,31)32)17-22-8-10-23(11-9-22)24-6-5-7-26(16-24)39(4,34)35/h5-16H,17-18H2,1-4H3
InChI key
PSOXOVKYGWBTPB-UHFFFAOYSA-N
Biochem/physiol Actions
GSK2033 has the ability to repress gluconeogenic gene expression stimulated by GC (glucocorticoids), without altering immune-responsive GR (GC receptor) target genes. It helps to target several nuclear receptors that can alter hepatic gene expression.
GSK2033 is an antagonist of the nuclear receptor liver-X-receptor (LXR) with pIC50 values of 7.0 for LXRα and 7.4 for LXRβ. Treatment of murine CD41 T cells with GSK2033 enhanced cellular proliferation and Th1/Th2/Th17 differentiation. In another study, the conjugated linoleic acid (CLA)-induced expression of efflux protein ATP-binding-cassette transporter A1 (ABCA1) was completely abolished by preincubation with GSK2033, showing that CLA mediated regulation of ABCA-1 expression is LXR dependent.
LXR antagonist
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.